This pill may treat diabetes; help patients shed those extra kilos

ANI | Updated: Oct 18, 2017 11:24 IST

This pill may treat diabetes- help patients shed those extra kilos .

Washington DC [USA], Oct 18 (ANI): A team of researchers has recently created a new pill that can significantly improve the health of people with diabetes and help to shed those extra kilos from their waistlines .

The findings indicated that among patients with type 2 diabetes, the drug semaglutide taken by pill resulted in better glycemic control than placebo over 26 weeks .

The results from 632 patients indicated that semaglutide allowed 71 percent of them to shed pounds .

It is believed this is the first type 2 diabetes pill to instigate weight loss .

Although several type 2 diabetes treatments are available, therapy selection involves consideration of the risks of adverse effects such as hypoglycemia (low blood sugar) or weight gain and complexity of treatment .

The oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonists (a class of drugs used for the treatment of type 2 diabetes), may improve acceptance and adherence for some patients compared with the injectable formulation of GLP-1 receptor agonists .

Melanie Davies from the University of Leicester, United Kingdom, and colleagues randomly assigned 632 patients with Type-2 diabetes and insufficient glycemic control to different doses and dose escalation of once-daily oral semaglutide; oral placebo; or once-weekly semaglutide by injection (subcutaneous) for 26 weeks .

They found that average change in hemoglobin Alc (HbA1c) level, from baseline to week 26, decreased with oral semaglutide and subcutaneous semaglutide and placebo; oral semaglutide reductions were significant vs placebo .

From an average baseline HbA1c level of 7 .9 percent, between 44 percent and 90 percent of patients receiving oral semaglutide achieved the target HbA1c level of less than seven percent .

Clinically relevant (five percent or more) weight loss was achieved in up to 71 percent of patients receiving oral semaglutide .

The research is published in The Jama Network Journals . (ANI)